EVAR术中预防性瘤囊周围动脉栓塞:减少II型内漏并改善瘤囊回缩
本研究比较了使用Ovation支架行EVAR时加用预防性分支血管及瘤囊栓塞(pPASE)与标准EVAR的两组择期患者。pPASE组36例(13.1%),标准EVAR组238例(86.9%),中位随访56个月。4年免于ELII率pPASE组84% vs 标准EVAR组50.7%(P=0.0002),pPASE组瘤囊均稳定或回缩,标准EVAR组10.9%出现瘤囊扩张(P=0.03)。
要点
- pPASE组4年免于ELII率为84%,标准EVAR组为50.7%(P=0.0002)。
- 4年时pPASE组AAA直径平均减小11 mm(95%CI 8-15),标准EVAR组减小5 mm(95%CI 4-6),P=0.0005。
- 因ELII再干预率pPASE组0.0% vs 标准EVAR组10.7%(P=0.1),差异趋向显著。
核心结论
- 作者认为,在接受EVAR的患者中行pPASE预防ELII安全有效,较标准EVAR显著改善瘤囊回缩并减少再干预需求。
研究设计与样本
- 本研究为两组择期队列比较,比较使用Ovation支架行EVAR时加用与不加用预防性分支血管及瘤囊栓塞的患者。
- pPASE组为本机构前瞻性、经机构审查委员会批准数据库中的患者,标准EVAR组数据来自Ovation研究性器械豁免试验的核心实验室裁定数据。
- pPASE组36例(13.1%),标准EVAR组238例(86.9%),中位随访56个月(33-60个月)。
主要发现
- 4年免于ELII率pPASE组为84%,标准EVAR组为50.7%(P=0.0002)。
- pPASE组所有动脉瘤大小保持稳定或回缩,标准EVAR组10.9%出现瘤囊扩张(P=0.03)。
- 4年时AAA直径平均减小pPASE组11 mm(95%CI 8-15),标准EVAR组5 mm(95%CI 4-6),P=0.0005。
- 4年全因死亡率和动脉瘤相关死亡率在两组间无差异。
- 因ELII再干预率pPASE组0.0% vs 标准EVAR组10.7%(P=0.1),差异趋向显著。
关键数值与推荐
- pPASE在EVAR术中施行,若腰动脉或肠系膜动脉通畅,则使用凝血酶、对比剂和明胶海绵进行栓塞。
临床怎么用
- 作者认为,在接受EVAR的患者中行pPASE预防ELII安全有效,可显著改善瘤囊回缩并减少再干预需求。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Type II endoleaks (ELII) are the most common complication following endovascular aneurysm repair (EVAR). Persistent ELII require continual surveillance and have been shown to increase the risk of Type I and III endoleaks, sac growth, need for intervention, conversion to open or even rupture, directly or indirectly. These are often difficult to treat following EVAR, and there are limited data regarding the effectiveness of prophylactic treatment of ELII. The aim of this study is to report the midterm outcomes of prophylactic perigraft arterial sac embolization (pPASE) performed in patients undergoing EVAR. METHODS: This is a comparison of 2 elective cohorts of those undergoing EVAR using the Ovation stent graft with and without prophylactic branch vessel and sac embolization. Patients who underwent pPASE at our institution had their data collected in a prospective, institutional review board-approved database. These were compared against the core lab-adjudicated data from the Ovation Investigational Device Exemption trial. Prophylactic PASE was performed at the time of EVAR with thrombin, contrast, and Gelfoam if the lumbar or mesenteric arteries were patent. Endpoints included freedom from ELII, reintervention, sac growth, all-cause mortality, and aneurysm-related mortality. RESULTS: Thirty-six patients (13.1%) underwent pPASE, while 238 patients (86.9%) had standard EVAR. Median follow-up was 56 months (33-60 months). The 4-year freedom from ELII estimates were 84% for the pPASE versus 50.7% for the standard EVAR group (P = 0.0002). All aneurysms in the pPASE group remained stable in size or demonstrated regression, whereas aneurysm sac expansion was seen in 10.9% of the standard EVAR group, P = 0.03. At 4 years, mean AAA diameter decreased by 11 mm (95% CI 8-15) in the pPASE group versus 5 mm (95% CI 4-6) for the standard EVAR group, P = 0.0005. There were no differences in the 4-year freedom from all-cause mortality and aneurysm-related mortality. However, the difference in reintervention for ELII trended toward significance (0.0% vs. 10.7%, P = 0.1). On multivariable analysis, pPASE was associated with a 76% reduction in ELII [(95% CI): 0.24 (0.08-0.65), P = 0.005]. CONCLUSIONS: These results suggest that pPASE in those undergoing EVAR is safe and effective in the prevention of ELII and significantly improves sac regression over standard EVAR while minimizing the need for reintervention.
引用
- Mathlouthi A, Yei K, Guajardo I, et al. Prophylactic Perigraft Arterial Sac Embolization During EVAR: Minimizing Type II Endoleaks and Improving Sac Regression. Ann Vasc Surg. 2023. PMID: 36906128. doi:10.1016/j.avsg.2023.02.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。